Actively Recruiting
Intralesional Cemiplimab Compared to Primary Surgery for Early Stage Cutaneous Squamous Cell Carcinoma A Phase 3 Randomized Study
Led by Regeneron Pharmaceuticals · Updated on 2026-09-16
369
Participants Needed
53
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of cemiplimab, a drug that helps the immune system target cancer cells by binding to a protein called PD-1, to treat early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. The study compares the effects of cemiplimab injected directly into the cancer lesion with the standard treatment of surgery. The main goals include assessing side effects and determining how well cemiplimab works compared to surgery. Participants will receive either intralesional injections of cemiplimab or undergo primary surgery, which could involve Mohs surgery or other methods ensuring complete margin assessment. The study design is randomized and parallel, meaning participants are assigned to one of these two groups. Treatments and evaluations occur according to a protocol, with follow-up to monitor response and safety. During the trial, participants will be monitored through various assessments including measuring event-free survival up to three years, evaluating complete response of the target lesion at week 13, and checking for adverse events over three years. Measurements of surgical and biopsy defect sizes will also be recorded. The study involves regular visits and follow-up evaluations to track treatment effects and safety throughout participation, which lasts up to the study completion date in 2030.
CONDITIONS
Brief Title
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here